Jane Healy - Concepedia

Author

Jane Healy

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J Healy, J. Healy, J.A. Healy, JANE A. HEALY, Jane A. Healy, Jane Anne Healy, Jane Healy, Love, Cassandra

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The University of Texas MD Anderson Cancer Center Duke University Duke Medical Center Howard Hughes Medical Institute

About

Jane Healy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.3K
2	Health Sciences	2	2	72
3	Diabetes	2	2	72
4	Biochemistry	1	1	44
5	Cell Biology	1	1	1.1K

Jane Healy

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma Anupama Reddy, Jenny Zhang, Nicholas S. Davis, Cell Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseMedicineImmunology	2017	1.1K
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, Annals of Oncology	2021	273
Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2 Andrea B. Moffitt, Sarah L. Ondrejka, Matthew McKinney, The Journal of Experimental Medicine	2017	170
GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo Jane Healy, Adrienne Nugent, Rachel E. Rempel, Blood	2016	63
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. Elena Garralda, Ammar Sukari, Nehal J. Lakhani, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsAnti-lag-3 Antibody Mk4280Immunotherapy	2021	46
Cholinergic Augmentation of Insulin Release Requires Ankyrin-B Jane Healy, Kent R. Nilsson, Hans E. Hohmeier, Science Signaling Metabolic SyndromeInsulin SignalingSignal TransductionCholinergic AugmentationBiochemistry	2010	44
Ankyrin-B Syndrome: Enhanced Cardiac Function Balanced by Risk of Cardiac Death and Premature Senescence Peter J. Mohler, Jane Healy, Hui Xue, PLoS ONE	2007	43
1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC M-J. Ahn, Jiaxin Niu, Dongwook Kim, Annals of Oncology Anti-tigit AntibodyMedicineImmunologyTherapeutic EfficacyImmune Checkpoint Inhibitor	2020	29
Ankyrin-B metabolic syndrome combines age-dependent adiposity with pancreatic β cell insufficiency Damaris N. Lorenzo, Jane Healy, Janell Hostettler, Journal of Clinical Investigation Rare Functional VariantsMetabolic DisorderKnockin MiceInsulin SignalingObesity	2015	28
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC Jiaxin Niu, Adnan Nagrial, Mark Voskoboynik, Annals of Oncology Anti-tigit AntibodyAnti-pd-1/pd-l1-naive NsclcImmunologyTherapeutic EfficacyImmune Checkpoint Inhibitor	2020	22

Page 1